Cell and Gene Outsourcing

  1. The Rise Of Chinese Biotechs And The Global CRO Question 8/25/2026

    As innovative therapies move beyond home markets, early planning across regulators and geographies helps avoid costly delays and protect trial budgets.

  2. Fill-Finish Solutions That Grow With Your Program 8/24/2026

    Moving from clinical to commercial manufacturing? Learn how flexible fill-finish solutions, scalable capacity, and integrated support can help drive efficiency and readiness.

  3. From Lipids To Launch: End-To-End Therapy Development 8/20/2026

    Explore integrated capabilities spanning lipid manufacturing, nanoparticle formulation, and more with support designed to move complex therapies from preclinical development through commercialization.

  4. Maintain Performance And Reduce Downtime 8/19/2026

    See how modernizing aging chromatography system controls can reduce downtime risk, improve serviceability, and support validated workflows through updated hardware and operating systems.

  5. New Promises, New Pressures, No Problem - Service Care Packages 8/19/2026

    Tighter production schedules leave little room for equipment disruption. Get support that can strengthen maintenance strategies, reduce operational risk, and help internal teams sustain performance.

  6. Bioprocessing Ecosystem For Downstream And Mixing 8/19/2026

    Modernize your drug manufacturing by exploring an integrated approach designed to support facility expansion, simplify implementation, and help production operations adapt as demand evolves.

  7. What Goes Into Restarting A Shelved Orphan Drug Candidate? 8/19/2026

    The Orphan Therapeutics Accelerator wants to help viable clinical-phase products reach patients. Its cofounder describes the complexity of rebooting a shelved candidate.

  8. Lonza Capabilities Update August 2026: Cell Line Development 8/18/2026

    Omeco Barrett, Principal Scientist, Global Process Development, highlights Lonza’s latest development in cell line expression technology and cell line development (CLD).

  9. Beyond Sensitivity: Building A Robust Multi-Matrix AAV Shedding Assays 8/17/2026

    AAV gene therapy shedding studies demand matrix-specific extraction, not a one-size-fits-all approach. See how validated multi-matrix assays achieve 99-100% accuracy across blood, saliva, semen, serum, and urine.

  10. mRNA Development And Manufacturing Services 8/17/2026

    Our end-to-end mRNA CDMO platform covers synthesis, LNP formulation, fill-finish, and QC under one roof — from early clinical to commercial scale-up to 100g.